Neurogene Inc. (NASDAQ:NGNE - Get Free Report) shares saw strong trading volume on Tuesday . 131,589 shares were traded during trading, an increase of 7% from the previous session's volume of 122,926 shares.The stock last traded at $56.17 and had previously closed at $66.00.
Wall Street Analysts Forecast Growth
Separately, HC Wainwright lowered their target price on Neurogene from $51.00 to $49.00 and set a "buy" rating on the stock in a research note on Monday, August 12th. Eight investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, the company presently has an average rating of "Buy" and a consensus price target of $51.00.
Get Our Latest Stock Report on Neurogene
Neurogene Stock Performance
The firm's 50-day simple moving average is $44.24 and its 200 day simple moving average is $38.99.
Neurogene (NASDAQ:NGNE - Get Free Report) last announced its quarterly earnings data on Friday, August 9th. The company reported ($1.09) earnings per share for the quarter, missing the consensus estimate of ($1.02) by ($0.07). The company had revenue of $0.93 million during the quarter. Equities research analysts anticipate that Neurogene Inc. will post -4.47 EPS for the current year.
Hedge Funds Weigh In On Neurogene
Several institutional investors and hedge funds have recently added to or reduced their stakes in NGNE. Vanguard Group Inc. boosted its holdings in shares of Neurogene by 906.5% during the 1st quarter. Vanguard Group Inc. now owns 507,483 shares of the company's stock valued at $25,831,000 after acquiring an additional 457,062 shares in the last quarter. Baker BROS. Advisors LP increased its stake in shares of Neurogene by 0.6% in the first quarter. Baker BROS. Advisors LP now owns 456,015 shares of the company's stock valued at $23,211,000 after buying an additional 2,499 shares during the period. Driehaus Capital Management LLC raised its holdings in Neurogene by 123.8% in the 2nd quarter. Driehaus Capital Management LLC now owns 102,187 shares of the company's stock valued at $3,719,000 after buying an additional 56,533 shares during the last quarter. Integral Health Asset Management LLC acquired a new stake in Neurogene during the 2nd quarter worth approximately $2,547,000. Finally, Marshall Wace LLP grew its holdings in Neurogene by 37.2% during the 2nd quarter. Marshall Wace LLP now owns 41,447 shares of the company's stock worth $1,508,000 after acquiring an additional 11,229 shares during the last quarter. Institutional investors own 52.37% of the company's stock.
About Neurogene
(
Get Free Report)
Neurogene Inc, a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease.
Featured Stories
Before you consider Neurogene, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Neurogene wasn't on the list.
While Neurogene currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
